| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-03-09 | MOR209/ES414 | metastatic castration-resistant prostate cancer |
1 | Emergent BioSolutions (USA - MD) Morphosys (Germany) | Cancer - Oncology |
| 2015-03-09 | X-linked hypophosphatemia (XLH) | Ultragenyx Pharmaceutical (USA - CA) | Rare diseases - Genetic diseases - Metabolic diseases | ||
| 2015-03-07 | XOMA 358 | hyperinsulinemic hypoglycemia | 1 | Xoma (USA - CA) | Rare diseases - Endocrinological diseases - Metabolic diseases |
| 2015-03-07 | asfotase alfa | hypophosphatasia | 2 | Alexion Pharmaceuticals (USA - CT) | Rare diseases - Genetic diseases - Metabolic diseases |
| 2015-03-05 | regorafenib (BAY 73-4506) | colorectal cancer |
3 | Bayer Healthcare (Germany) | Cancer - Oncology |
| 2015-03-05 | Ropeginterferon alfa 2b (mono-pegylated Interferon alpha 2b - AOP2014/P1101) | polycythaemia vera | 3 | AOP Orphan Pharmaceuticals (Austria) | Rare diseases |
| 2015-03-05 | BMS-955176 | HIV-1 infection |
2a | BMS (USA - NY) | Infectious diseases |
| 2015-03-05 | octreotide capsules | acromegaly |
3 | Chiasma (USA - MA) | Hormonal diseases - Rare diseases - Endocrine diseases |
| 2015-03-05 | cenderitide | chronic heart failure |
2 | Capricor Therapeutics (USA - CA) | Cardiovascular diseases |
| 2015-03-04 | Fexeric®/Auryxia™ (ferric citrate coordination complex) | hyperphosphataemia in adult patients with chronic kidney disease | 3 | Keryx Biopharmaceuticals (USA - NY) | Kidney diseases - Metabolic diseases - Renal diseases |
| 2015-03-04 | MicOryx/Montanide® ISA-51 VG | advanced microsatellite instable (MSI-H-) colorectal cancer |
1-2a | Oryx (Germany) | Cancer - Oncology |
| 2015-03-04 | ASP4132 | lymphoma, advanced refractory solid tumors | 1 | Astellas Pharma (Japan) | Cancer - Oncology |
| 2015-03-03 | vapendavir | rhinovirus (HRV) infection in patients with moderate-to-severe asthma |
2b | Biota Pharmaceuticals (USA - GA) | Infectious diseases - Respiratory diseases |
| 2015-03-03 | solnatide - AP301 - synthetic peptide L-cysteine, L-cysteinylglycyl-L-glutaminyl-L-arginyl-L-.alpha.-glutamyl-Lthreonyl-L-prolyl-L-.alpha.-glutamylglycyl-L-alanyl-L-.alpha.-glutamyl-L-alanyl-L-lysyl-L-prolyl-Ltryptophyl-L-tyrosyl-,cyclic (1.fwdarw.17)-disulfide | primary graft dysfunction following lung transplantation | 2a | Apeptico (Austria) | Rare diseases - Transplantation - Lung diseases |
| 2015-03-03 | citarinostat (ACY-241) | multiple myeloma | 1 | Acetylon Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2015-03-02 | DUR-928 | NASH (non-alcoholic steatohepatitis) |
1 | Durect Corporation (USA - CA) | Hepatic diseases - Liver diseases - Metabolic diseases |
| 2015-03-02 | vaccine against Chikungunya fever | Chikungunya fever |
1 | Themis Bioscience (Austria) | Infectious diseases |
| 2015-03-01 | Kyprolis® (carfilzomib) | multiple myeloma |
3 | Amgen (USA - CA) | Cancer - Oncology |
| 2015-02-27 | RTH258 | neovascular wet age-related macular degeneration (AMD) | 2 | Alcon (USA -TX), a Novartis subsidiary (Switzerland) | Ophtalmological diseases |
| 2015-02-27 | 3C23K monoclonal antibody (GM102) | ovarian cancer | preclinical | GamaMabs Pharma (France) | Cancer - Oncology |
